| Literature DB >> 26711254 |
Iwona I Smaczynska-de Rooij1, Christopher J Marklew1, Ellen G Allwood1, Sarah E Palmer1, Wesley I Booth1, Ritu Mishra2, Martin W Goldberg2, Kathryn R Ayscough3.
Abstract
The family of dynamin proteins is known to function in many eukaryotic membrane fusion and fission events. The <span class="Species">yeast dynamin-related protein Vps1 functions at several stages of membrane trafficking, including Golgi apparatus to endosome and vacuole, peroxisomal fission, and endocytic scission. We have previously shown that in its endocytic role, Vps1 functions with the amphiphysin heterodimer Rvs161/Rvs167 to facilitate scission and release of vesicles. Phosphoproteome studies of Saccharomyces cerevisiae have identified a phosphorylation site in Vps1 at serine 599. In this study, we confirmed this phosphorylation event, and we reveal that, like Rvs167, Vps1 can be phosphorylated by the yeast cyclin-associated kinase Pho85 in vivo and in vitro. The importance of this posttranslational modification was revealed when mutagenesis of S599 to a phosphomimetic or nonphosphorylatable form caused defects in endocytosis but not in other functions associated with Vps1. Mutation to nonphosphorylatable valine inhibited the Rvs167 interaction, while both S599V and S599D caused defects in vesicle scission, as shown by both live-cell imaging and electron microscopy of endocytic invaginations. Our data support a model in which phosphorylation and dephosphorylation of Vps1 promote distinct interactions and highlight the importance of such regulatory events in facilitating sequential progression of the endocytic process.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26711254 PMCID: PMC4760221 DOI: 10.1128/MCB.00833-15
Source DB: PubMed Journal: Mol Cell Biol ISSN: 0270-7306 Impact factor: 4.272
Yeast strains used in this study
| Strain | Genotype | Note |
|---|---|---|
| KAY378 | DDY1563 ( | |
| KAY446 | Invitrogen | |
| KAY1539 | Invitrogen | |
| KAY1542 | Invitrogen | |
| KAY1544 | Invitrogen | |
| KAY1661 | Invitrogen | |
| KAY1685 | Invitrogen | |
| KAY1668 | LRB758 ( | |
| KAY1671 | LRB756 ( | |
| KAY1095 | E. Hettema | |
| KAY1096 | E. Hettema | |
| KAY1337 | Ayscough laboratory | |
| KAY1369 | Ayscough laboratory | |
| KAY1462 | Ayscough laboratory | |
| KAY438 | ||
| KAY302 | Ayscough laboratory | |
| KAY389 | Ayscough laboratory | |
| KAY1756 | Ayscough laboratory | |
| KAY1761 | Ayscough laboratory | |
| KAY1762 | Ayscough laboratory | |
| KAY1621 | Ayscough laboratory | |
| KAY1832 | Ayscough laboratory | |
| KAY1898 | This study | |
| KAY1899 | This study | |
| KAY1893 | ||
| KAY1894 | KAY389 × KAY1893 cross | This study |
| KAY1895 | KAY1756 × KAY1893 cross | This study |
| KAY1896 | KAY1762 × KAY1893 cross | This study |
| KAY1897 | KAY1761 × KAY1893 cross | This study |
| KAY1467 | Ayscough laboratory |
Plasmids used in this study
| Plasmid | Description | Origin or reference |
|---|---|---|
| pKA552 | Gal4BD-Vps1(276-704) | E. Hettema laboratory |
| pKA167 | pGBD-C3::Gal4BD | |
| pKA163 | pGAD-C2::GalAD | |
| pKA730 | GalAD-Rvs167 | |
| pKA777 | Gal4BD-Vps1(276-704) S599V | This study |
| pKA778 | Gal4BD-Vps1(276-704) S599D | This study |
| pKA544 | ||
| pKA677 | pKA544 with | This study |
| pKA781 | pKA544 with | This study |
| pKA782 | pKA544 with | This study |
| pKA836 | YCplac111-VPS1-GFP own promoter; | |
| pKA859 | YepLac112- | Hicke Laboratory |
| pKA902 | pKA836 with | This study |
| pKA903 | pKA836 with | This study |
| pKA695 | YCplac111- | This study |
| pKA904 | pKA695 with | This study |
| pKA905 | pKA695 with | This study |
| pKA850 | His-tagged Vps1 wild type | |
| pKA971 | pKA850 with | This study |
| pKA972 | pKA850 with | This study |
| pKA1051 | pGal1/10-GST-GST-PHO85 | Open BioSystems |
FIG 1Vps1 phosphorylation in vivo and in vitro. (A) Vps1-HA was immunoprecipitated from log-phase cells and subjected to analysis by mass spectrometry as described in the text. Peptides carrying phosphorylated residues are highlighted. High-confidence sites are shown in red (high-confidence identity, PEP < 0.01; high-confidence localization, 1% false-localization rate). Other sites (blue) were identified either with medium confidence (PEP > 0.01) but with high-confidence localization or with high confidence identity (PEP < 0.01) but low-confidence localization (>1% false-localization rate). (B) Immunoprecipitated Vps1 was incubated in the presence (+) or absence (−) of calf intestinal AP. Following AP treatment, a fraction of the HA-tagged Vps1 was incubated in the presence of GST-Pho85, as described in the text. Extracts were separated both on an Any Kd gradient gel or on SDS-7.5% PAGE containing 20 μM Phos-tag additive, followed by blotting and probing for Vps1 with anti-HA antibodies. (C) Whole-cell extracts were made from strains with deletions of kinase genes. Extracts were separated on gels (10% gel; 100 μM Phos-tag) and blotted as described in the text. The blots were probed with anti-Vps1 antibodies. WT, wild type. (D) The Pho85 consensus site at Ser599 was mutagenized to valine or aspartate. Extracts from cells expressing these were made, separated, blotted, and probed with antibody. The pho85 deletion and vps1 mutants were not isogenic, so different wild-type strains were used for extracts. Numbers indicate the sizes of molecular weight markers.
FIG 2Vps1 S599 mutants can perform Vps1-requiring functions in cells. (A) Cells expressing wild-type VPS1, a vps1 deletion, or the Vps1 S599V and S599D mutants were assessed for growth at 30°C and 37°C. As shown, both the S599V and S599D mutants rescue the temperature sensitivity associated with the complete deletion. (B) Carboxypeptidase Y maturation was assessed in cells, and only the deletion strain was observed to have reduced levels and to show the presence of the higher-molecular-weight immature CPY band. (C) Localization of the GFP-Snc1 reporter that cycles from Golgi apparatus to plasma membrane to endosomes was analyzed for changes in distribution. (D) Vacuolar morphology was assessed following labeling with the lipophilic dye FM4-64. (E) A Vps10-2×GFP vps1Δ strain was crossed with strains expressing the wild type or vps1 mutants to determine whether the mutants rescue the retrograde trafficking defect associated with vps1 deletion. (F) Peroxisome morphology was assessed in cells carrying a vps1 dnm1 double deletion with VPS1 and the vps1 mutants reintroduced.
FIG 3Effects of Vps1 mutations on behavior of an early endocytic marker, Sla1-GFP. (A) The lifetimes of Sla1-GFP at endocytic sites were measured. Mean lifetimes and numbers of patches counted are shown. Only the vps1 deletion strain showed a lifetime significantly different from that of the wild-type strains. (B) The behavior of Sla1-GFP patches was assessed and categorized as indicated. Patches were considered to endocytose normally, show no invagination, show retraction, or show invagination followed by a delay in the invaginated state. Examples of kymographs depicting these behaviors are shown. Error bars indicate standard deviations.
FIG 4Localization of Vps1 phosphomutants to endocytic sites. (A) Bimolecular fluorescence assay with Vps1 tagged with the N terminus of Venus (VN) and Rvs167 with the C terminus of Venus (VC). The wild type and both Vps1 phosphomutants were analyzed. Controls on the right demonstrate absence of signal on expression of either half of the Venus construct. (B) Localization of Vps1 to endocytic sites was determined by colocalization of Vps1-GFP with Abp1-mCherry. On the right of the whole-cell images are sequential images from time-lapse movies of individual patches. The arrows depict Vps1-GFP colocalization with Abp1-mCherry.
FIG 5Effect of Vps1 S599 mutations on amphiphysins. (A) The lifetimes of the amphiphysin Rvs167-GFP at endocytic sites were measured for each of the strains indicated and categorized as two stages: either the lifetime at the membrane or time in invagination/movement. Total mean lifetimes are indicated. Error bars indicate standard deviations. (B) Representative kymographs of Rvs167-GFP in each of the strains. The time course for kymographs was 45 s. (C) Yeast two-hybrid analysis was used to investigate interactions between the Vps1 C-terminal region (amino acids 276 to 704) as a Gal4 binding domain fusion and Rvs167 fused to the Gal4 activation domain. Controls with empty plasmids are shown. −LT, medium lacking leucine and tryptophan; −HLT, medium lacking histidine, leucine, and tryptophan. (D) Rvs167 overexpression on a 2μ inhibits cell growth at 37°C. The effect of cooverexpression of Vps1 on this phenotype was investigated. Both wild-type Vps1 and Vps1 S599D were able to rescue the temperature sensitivity.
FIG 6Effect of S599 mutation on ultrastructure of plasma membrane invaginations. (A) Cells expressing the wild type or vps1 mutations were high-pressure frozen and processed for electron microscopy as described in the text. The lengths of invaginations observed in cells were measured. Each spot represents one measurement, and means are indicated. Both S599D and S599V cause a statistically significant increase in invagination length. Error bars indicate standard deviations. (B) Images of wild-type invaginations, as well as average and long invaginations for the S599V and S599D mutants.
FIG 7In vitro analysis of Vps1 and the S599 mutants. (A) Recombinant Vps1 was purified, and oligomers were visualized when samples were processed and stained as described in the text. Shown are examples of single rings (three images for each protein) and double-ring structures. (B) Lipid binding preferences were investigated using a PIP strip assay following incubation with purified proteins and detection with anti-His antibodies. (C) PIP arrays were performed using wild-type and S599D mutant proteins to determine whether differences between binding on the PIP strip were due to a complete block in binding caused by the mutation or whether there was a more subtle change in lipid affinity.